• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Researchers identify target for shutting down growth of prostate cancer cells

Bioengineer by Bioengineer
March 6, 2014
in Cancer
Reading Time: 2 mins read
1
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Scientists at UT Southwestern Medical Center have identified an important step toward potentially shutting down the growth of prostate cancer cells.

Researchers identify target for shutting down growth of prostate cancer cells

Dr. Ralf Kittler, Assistant Professor of Pharmacology at UT Southwestern.

Dr. Ralf Kittler, Assistant Professor of Pharmacology, studies ERG, a protein that facilitates the transformation of normal prostate cells into cancer cells. His lab found that an enzyme called USP9X protects ERG from degradation and subsequently found that a molecule called WP1130 can block USP9X and lead to the destruction of ERG.

“We now have a target that we could potentially exploit to develop a drug for treatment,” said Dr. Kittler, UT Southwestern’s first Cancer Prevention and Research Institute of Texas (CPRIT) Scholar in Cancer Research.

The findings are published in the Proceedings of the National Academy of Sciences. Dr. Kittler’s team tested the molecule successfully in mice, but the process needs to be improved to be effective in humans, he said. Toxicity and side effects also will be tested, so much work lies ahead, and it could take many years before knowing whether the molecule can be developed into a drug that is effective in humans.

“It’s a good start, and now we are in a position to develop the finding further in an effort to move into the clinic,” said Dr. Kittler, the John L. Roach Scholar in Biomedical Research of UT Southwestern’s Endowed Scholars Program.

The observation may represent an important advance against one of the major cancer killers. Prostate cancer is the most common type of cancer in men and the second most common cause of male cancer death in the United States. The disease caused nearly 30,000 deaths in 2013, according to the American Cancer Society.

Metastatic prostate cancer currently is treated with drugs that inhibit a protein called Androgen Receptor. This treatment initially halts cancer growth, but eventually the cancer becomes resistant to the drugs. Dr. Kittler’s findings offer a new avenue of research.

Dr. Kittler’s research was supported by CPRIT. Other UT Southwestern researchers involved include Dr. Payal Kapur, Associate Professor of Pathology and Urology; Dr. Yair Lotan, Professor of Urology; Dr. Ganesh Raj, Associate Professor of Urology; and Dr. Jer-Tsong Hsieh, Professor of Urology.

Story Source:

The above story is based on materials provided by The University of Texas Southwestern Medical Center, Patrick McGee.

Share12Tweet8Share2ShareShareShare2

Related Posts

Study Reveals Hidden Immune Defense Mechanism That Could Combat Cancer

October 23, 2025

Mayo Clinic Partners in Groundbreaking Study Demonstrating Enhanced Survival Rates for Early Breast Cancer Patients

October 23, 2025

Elevated Levels of Specific Protein Linked to Impaired Progression in High-Risk Pediatric Neuroblastoma

October 23, 2025

Detecting Colon Cancer DNA in Blood Could Inform Chemotherapy Choices: Study Finds

October 23, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1277 shares
    Share 510 Tweet 319
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    308 shares
    Share 123 Tweet 77
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    165 shares
    Share 66 Tweet 41
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    132 shares
    Share 53 Tweet 33

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Impact of OSA on Muscle and Fat in Adults

Examining Patients’ Financial Strain at Hospital Clinics

Internet Use and Loneliness in China’s Seniors

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 66 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.